Myeloid NGS Analyses of Paired Samples from Bone Marrow and Peri-pheral Blood Yield Concordant Results: A Prospective Cohort Analysis of the AGMT Study Group.

Jansko-Gadermeir, B; Leisch, M; Gassner, FJ; Zaborsky, N; Dillinger, T; Hut-ter, S; Risch, A; Melchardt, T; Egle, A; Drost, M; Larcher-Senn, J; Greil, R; Pleyer, L. Cancers (Basel) . 2023 Apr 14;15(8):2305. doi: 10.3390/cancers15082305.

Pretreatment 18-FDG-PET/CT parameters can serve as prognostic ima-ging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy.

Grambozov, B; Kalantari, F; Beheshti, M; Stana, M; Karner, J; Ruznic, E; Zellinger, B; Sedlmayer, F; Rinnerthaler, G; Zehentmayr, F. Radiother Oncol. 2023 Aug;185:109728. doi: 10.1016/j.radonc.2023.109728. Epub 2023 Jun 9.

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.

Nowakowski, GS; Yoon, DH; Mondello, P; Joffe, E; Peters, A; Fleury, I; Greil, R; Ku, MT; Marks, R; Kim, K; Zinzani, PL; Trotman, J; Sabatelli, L; Waltl, EE; Winderlich, M; Sporchia, A; Kurukulasuriya, NC; Cordoba, R; Hess, G; Salles, G. Ann Hematol. 2023 Jul;102(7):1773-1787. doi: 10.1007/s00277-023-05196-4. Epub 2023 May 12.

S-1 maintenance therapy in Caucasian patients with metastatic esopha-gogastric adenocarcinomaefinal results of the randomized AIO MATEO phase II trial.

Stocker, G; Lorenzen, S; Ettrich, T; Herz, AL; Longo, F; Kiani, A; Venerito, M; Trojan, J; Mahlberg, R; Moosmann, N; Chibaudel, B; Kubicka, S; Greil, R; Daum, S; Geissler, M; Larcher-Senn, J; Keller, G; Lordick, F; Haag, GM. ESMO Open. 2023 Jun;8(3):101572. doi: 10.1016/j.esmoop.2023.101572. Epub 2023 Jun 2.

Barriers to patient access of CAR T cell therapies in Austria.

Hopfinger, G; Rupp, B; Greil, R. memo 16, 79–90 (2023). https://doi.org/10.1007/s12254-022-00859-w.

How I treat diffuse large B-cell lymphoma.

Melchardt, T; Egle, A; Greil, R. ESMO Open.2023 Feb;8(1):100750. doi: 10.1016/j.esmoop.2022.100750. Epub 2023 Jan 10.

Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperati-ve chemotherapy with the FLOT protocol.

Huemer, F; Hecht, S; Scharinger, B; Schlintl, V; Rinnerthaler, G; Schlick, K; Heregger, R; Melchardt, T; Wimmer, A; Mühlbacher, I; Koch, OO; Neureiter, D; Klieser, E; Seyedinia, S; Beheshti, M; Greil, R; Weiss, L. J Cancer Res Clin Oncol. 2023 Jul;149(7):3051-3064. doi: 10.1007/s00432-022-04096-w. Epub 2022 Jul 21.

Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMT.

Pleyer, L; Heibl, S; Tinchon, C; Vallet, S; Schreder, M; Melchardt, T; Stute, N; Föhrenbach Quiroz, KT; Leisch, M; Egle, A; Scagnetti, L; Wolf, D; Beswick, R; Drost, M; Larcher-Senn, J; Grochtdreis, T; Vaisband, M; Hasenauer, J; Zaborsky, N; Greil, R; Stauder, R. Cancers (Basel). 2023 Feb 22;15(5):1388. doi: 10.3390/cancers15051388.

The Class IIA Histone Deacetylase (HDAC) Inhibitor TMP269 Downregulates Ribosomal Proteins and Has Anti-Proliferative and Pro-Apoptotic Effects on AML Cells.

Urwanisch, L; Unger, MS; Sieberer, H; Dang, HH; Neuper, T; Regl, C; Vetter, J; Schaller, S; Winkler, SM; Kerschbamer, E; Weichenberger, CX; Krenn, PW; Luciano, M; Pleyer, L; Greil, R; Huber, CG; Aberger, F; Horejs-Hoeck, J. Cancers (Basel).2023 Feb 7;15(4):1039. doi: 10.3390/cancers15041039.

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.

Harrington, KJ; Burtness, B; Greil, R; Soulieres, D; Tahara, M; de Castro, G; Psyrri, A; Brana, I; Baste, N; Neupane, P; Bratland, A; Fuereder, T; Hughes, BGM; Mesia, R; Ngamphaiboon, N; Rordorf, T; Ishak, WZW; Lin, JX; Gumuscu, B; Swaby, RF; Rischin, D. J Clin Oncol.2023 Feb 1;41(4):790-802. doi: 10.1200/JCO.21.02508. Epub 2022 Oct 11.